Kim, Stephanie I.;
Szeto, Andy H.;
Morgan, Katherine P.;
Brower, Blaine;
Dunn, Mary W.;
Khandani, Amir H.;
Godley, Paul A.;
Rose, Tracy L.;
Basch, Ethan M.;
Milowsky, Matthew I.;
Whang, Young E.;
Crona, Daniel J.
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer
Beteiligte:
Kim, Stephanie I.;
Szeto, Andy H.;
Morgan, Katherine P.;
Brower, Blaine;
Dunn, Mary W.;
Khandani, Amir H.;
Godley, Paul A.;
Rose, Tracy L.;
Basch, Ethan M.;
Milowsky, Matthew I.;
Whang, Young E.;
Crona, Daniel J.
Erschienen:
Public Library of Science (PLoS), 2021
Erschienen in:
PLOS ONE, 16 (2021) 6, Seite e0253021
Sprache:
Englisch
DOI:
10.1371/journal.pone.0253021
ISSN:
1932-6203
Entstehung:
Anmerkungen:
Beschreibung:
IntroductionRadium-223, abiraterone, and enzalutamide have each been shown to significantly improve survival as monotherapy in patients with metastatic castration-resistant prostate cancer. However, effects of combination radium-223 plus abiraterone or enzalutamide on survival and safety remain unclear.Patients and methodsThis single-center retrospective cohort study used electronic health record data of patients with metastatic castration-resistant prostate cancer and bone metastases who were treated with radium-223 between April 1, 2014 and February 19, 2019. Patients who received radium-223 monotherapy were compared to patients who received a combination of radium-223 plus either abiraterone or enzalutamide. The primary endpoint was overall survival. Secondary endpoints included progression-free survival, time to symptomatic skeletal event, symptomatic skeletal event-free survival, and incidence of drug-related adverse events. Time-to-event analyses were estimated by log rank tests using Kaplan-Meier curves. Hazard ratios and 95% confidence intervals were derived from Cox proportional hazards models. Chi-square tests evaluated difference in serious adverse events between the two arms.ResultsA total of 60 patients met inclusion criteria (n = 41 in the monotherapy arm, n = 19 in the combination arm). Differences in median overall survival were not observed (12.7 vs. 12.8 months; HR 1.15, 95% CI 0.59–2.23; P = 0.68), but median progression-free survival was significantly longer in the combination arm (7.6 vs. 4.9 months; HR 1.94, 95% CI 1.11–3.40; P = 0.02). Significant differences were not observed in time to first SSE (P = 0.97), SSE-free survival (P = 0.16), or in the overall incidence of serious adverse events (P = 0.45).ConclusionCombination radium-223 plus abiraterone or enzalutamide did not improve overall survival, but prolonged progression-free survival without increasing the incidence of serious adverse events in metastatic castration-resistant prostate cancer patients with bone metastases. However, these results are limited by small numbers and patient selection inherent in retrospective analysis.